# Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer

> **NCT04326153** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 30 (actual)

## Conditions studied

- IIIA Stage Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Sintilimab Injection

## Key facts

- **NCT ID:** NCT04326153
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-20
- **Primary completion:** 2023-09-06
- **Final completion:** 2027-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04326153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04326153, "Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04326153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*